FIREFLY NEUROSCIENCE, INC. (AIFF): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, at the 2026 annual meeting of stockholders (the “ Annual Meeting ”) of Firefly Neuroscience, Inc., a Del

Event · Shareholder vote
Original reporting
Published Aug 7, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$AIFF
Neutral
medium confidence
Mentioned
$AIFF
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AIFFNeutralLow
01

Why it matters

Equity plan share availability increased by 2,000,000 shares, while authorized common shares were reduced from 5,001,000,000 to 100,000,000, with preferred authorized at 1,000,000. These changes can influence dilution expectations and future compensation flexibility.

02

Market read

This is a governance and equity-structure update from shareholder votes, not an earnings or clinical catalyst.

03

What to watch

Traders may be over-weighting the plan share increase without knowing actual burn rate, grant cadence, and whether the company has other dilutive instruments outstanding.

Relevance 6/10Novelty 4/10Timing: post-annual-meeting filing, effective Aug. 5, 2026

Background

The 8-K reports results from Firefly Neuroscience’s Aug. 5, 2026 annual meeting, including approval of a long-term incentive plan amendment and a certificate of amendment to authorized shares.

Company-level read

Ticker impact

$AIFFNeutralMedium confidence
Context

Firefly Neuroscience shareholders approved an equity plan share increase of 2,000,000 shares and a charter authorization reducing total authorized shares effective Aug. 5, 2026.

Expected impact

Near-term impact likely limited unless traders extrapolate higher future dilution from the plan share increase.

Evidence & confidence

This is an 8-K describing shareholder-approved plan and charter amendments, with no new financial guidance or operational catalyst disclosed in the provided text.

Market effects

Minor read-through for small-cap biotech governance and equity-compensation practices; not a sector-wide catalyst.

No clear regional spillover beyond Nasdaq-listed small-cap sentiment.

No material global market linkage indicated.

Counterpoint

The charter authorization reduction could be viewed as a constraint on authorized share overhang, partially offsetting the plan share increase.

Key entities

  • Firefly Neuroscience, Inc.

    Nasdaq-listed company filing the 8-K; subject of the shareholder approvals and charter/plan amendments.

  • Arun Menawat

    Class III director elected at the annual meeting to serve until 2029.

  • CBIZ Canada, LLP

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$AIFFHighAI 8/10

AI Stock Firefly Neuroscience (NASDAQ: AIFF) Soars on First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) stock surged 32.77% after announcing a partnership with NeuroSigma to expand access to the FDA-cleared Monarch eTNS(R) System, a non-drug treatment for pediatric ADHD. The stock traded at $1.58 on high volume. Firefly's Evoke(TM) platform provides AI-powered brain function analytics to clinicians. According to a 2024 study, approximately 7.1 million U.S. children have been diagnosed with ADHD, with nearly one-third receiving no treatment.

$AIFFHigh

Firefly Hikes on Partnering with NeuroSigma

Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.

$COSTHigh

The Best Recession-Proof Consumer Stock to Buy With $1,000 Before 2027

Costco (COST) reported Q4 2026 sales growth of 11.2%, with comparable sales up 9.4%. The company announced a $30 special dividend, its highest ever, boosting its stock by 5%. Costco's unique model, offering low prices and membership fees, drives loyalty and sales, especially during economic downturns. Gas stations and e-commerce are key growth drivers, with digitally-enabled sales up 20% YoY.

$MARAMed

MARA prices $185M debt offering after $1.1B Bitcoin sale

MARA priced an $185M debt offering at 8.75% interest, maturing in 2032, to finance its $1.5B acquisition of Long Ridge Energy. The deal includes a 485MW power plant and land for potential data centers. MARA recently sold $1.1B in Bitcoin to repay debt. Long Ridge generated $144M in annualized adjusted EBITDA, but interest payments may consume nearly half.

$RIOLow

Rio Tinto commits US$250m to address damage from Bougainville's Panguna mine

Rio Tinto will contribute $250m to a fund addressing environmental and human rights impacts of the Panguna mine, per an agreement with Bougainville Copper Limited, the Autonomous Bougainville Government, and community leaders. The fund aims to support practical responses to identified impacts and social projects. Details will be developed in consultation with communities.